-ETV/ News 18 Claiming that the excessive use of chemical fertilizers and pesticides destroyed Punjab in the two decades, volunteers from Punjab - once an agri-role model-have cautioned Madhya Pradesh against the same. These volunteers from Kheti Virasat Mission - a group of volunteer activists from different fields working in Punjab for promoting organic farming, said this while participating in Vikalp Mela as part of Bhopal gas tragedy's 30th anniversary events in...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...

-The Hindu Business Line Through the ‘Sukrutham' scheme, the Kerala Government aims to take advanced Cancer treatment to the poorest Kerala: "We have two options, medically and emotionally: give up or fight like hell," Lance Armstrong, champion cycle racer, who recovered from advanced testicular cancer once said about his battle against cancer. The American, fortunately, had the money to pay for the extremely expensive treatment. But, for the majority of 1.75 lakh...

-Kafila.org Dear Prime Minister Modi ji, We, the undersigned, wish to share with you some of our concerns on India's position on intellectual property (IP), particularly in the context of bilateral relations between the United States of America and India. We gather from the US-India Joint Statement dated 30 September 2014 that the Indian Government (a)greeing on the need to foster innovation in a manner that promotes economic growth...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...